ASH 2025 | Odronextamab + lenalidomide in R/R FL: first results from part 1 of the Phase III OLYMPIA-5 trial

OLYMPIA-5 study is a Phase II study that is devoted to follicular lymphoma in the relapsed/refractory setting and evaluating the combination of Odronextamab, another bispecific CD3xCD20 antibody, plus lenalidomide. The result presented at this meeting is the result of part one of the study, in which the patients enrolled were tested to receive Odronextamab at a lower dose, 40 milligrams combined, with lenalidomide, at a standard dose of 20 milligrams every 21 days, every month, or the higher dose of Odronextamab, 80 milligrams. Again, with a fixed duration of treatment for one year. 

So the results of this part of the study, the preliminary results, just to show the feasibility and the safety of the combination and to select the appropriate dose for the randomized part of the study. The dose of 80 milligrams was proved to be safer, with again the CRS rate that was not different from what we have already observed with Odronextamab when used as a single agent. So this dose was selected for the future study that is ongoing. The future study is the phase 3 randomized study comparing Odronextamab and Lenalidomide to standard rituximab and Lenalidomide, which is the standard treatment for relapsed/refractory lymphoma. So we’ll see the results of the phase 3 study, of course, not yet, as this meeting may be next year.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.